Immunotherapeutic agents
US5968945A · kind A · utility
37Cited by
0References
12Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Jan 14, 1998 |
| Grant date | Oct 19, 1999 |
| Priority date | — |
| Expiry date | Jan 14, 2018 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07D209/46
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Novel amides and imides are inhibitors of tumor necrosis factor.alpha. and phosphodiesterase and can be used to combat cachexia, endotoxic shock, retrovirus replication, asthma, and inflammatory conditions. Typical embodiments include 3-(1,3-dioxobenzo[f]isoindol-2-yl)-3-(3-cyclopentyloxy-4-methoxyphenyl)pro pionamide and 3-(1,3-dioxo-4-azaisoindol-2-yl)-3-(3,4-dimethoxyphenyl)-propionarnide.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.